Volume | 541 |
|
|||||
News | - | ||||||
Day High | 0.142 | Low High |
|||||
Day Low | 0.13 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Ampio Pharmaceuticals Inc (PK) | AMPE | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.13 | 0.13 | 0.142 | 0.142 | 0.13 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
20 | 541 | US$ 0.13285 | US$ 72 | - | 0.13 - 0.56 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
14:16:57 | 2 | US$ 0.1301 | USD |
Ampio Pharmaceuticals Inc (PK) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
158.95k | 226.29M | - | 0 | -8.63M | -7.60 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Ampio Pharmaceuticals (PK) News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AMPE Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.13 | 0.2116 | 0.13 | 0.1576703 | 1,076 | 0.012 | 9.23% |
1 Month | 0.22 | 0.41 | 0.13 | 0.2134385 | 3,845 | -0.078 | -35.45% |
3 Months | 0.15 | 0.56 | 0.13 | 0.2737406 | 8,135 | -0.008 | -5.33% |
6 Months | 0.15 | 0.56 | 0.13 | 0.2737406 | 8,135 | -0.008 | -5.33% |
1 Year | 0.15 | 0.56 | 0.13 | 0.2737406 | 8,135 | -0.008 | -5.33% |
3 Years | 0.0206 | 0.56 | 0.01 | 0.0242812 | 1,692,470 | 0.1214 | 589.32% |
5 Years | 0.0206 | 0.56 | 0.01 | 0.0242812 | 1,692,470 | 0.1214 | 589.32% |
Ampio Pharmaceuticals (PK) Description
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The product pipeline includes new uses for previously approved drugs, some of which are now starting clinical trials, and new molecular entities ("NMEs"). A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize the company's product development programs. |